Showing results (141-150 of 259) with videos related to
Sort By:
Pageof 26
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 14, 2017
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitorsBin-Chi Liao, Ya-Ying Bai, Jih-Hsiang Lee, et al.JTO Clinical and Research Reports|September 30, 2021
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in <i>EGFR</i> T790M-Positive NSCLCBin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, et al.British Journal of Cancer|December 23, 2016
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6Yi-Long Wu, Lecia V Sequist, Cheng-Ping Hu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i>-mutant Non-small Cell Lung CancerHelena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, et al.British Journal of Clinical Pharmacology|January 31, 2018
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinibKarthick Vishwanathan, Paul A Dickinson, Karen So, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 13, 2019
Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unitEmily Han-Chung Hsiue, Pei-Lin Lee, Yung-Hsuan Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2016
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases ActivityPeter Ballard, James W T Yates, Zhenfan Yang, et al.Therapeutic Advances in Medical Oncology|November 3, 2022
Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinomaChia-Ling Chang, Min-Shu Hsieh, Jin-Yuan Shih, et al.Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trialsMartin Schuler, Luis Paz-Ares, Lecia V Sequist, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final AnalysisChong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, et al.Pageof 26